In a regulatory filing, Phathom Pharmaceuticals (PHAT) disclosed that its director bought 10K shares of common stock on March 13th in a total transaction size of $44.2K. Shares are up 6.6% afterhours at $5.16.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHAT:
- Phathom Pharmaceuticals’ Earnings Call: Growth and Challenges
- Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs
- Phathom Pharmaceuticals price target lowered to $18 from $28 at Guggenheim
- Phathom Pharmaceuticals price target lowered to $19 from $27 at Craig-Hallum
- Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating